Oncologia hepàtica (BCLC)

Projectes destacats

Rational to modulate the microbiome-induced endoplasmic reticulum stress as tool to avoid the immune evasion in Hepatocellular Carcinoma (RETO)

Investigador/a principal: María Reig Monzón.
Finançador: Institut d'Investigacions Biomèdiques August Pi i Sunyer (Entidad de origen); Asociación Española Contra el Cáncer .

Codi: PRYCO234831REIG.

Durada: 01/01/2024 - 01/01/2028
Plasticidad tumoral y la regulación de anhidrasa carbónica 9 en carcinoma hepatocelular. Base racional para modular la evasión inmunológica y mejorar la respuesta al tratamiento.

Investigador/a principal: María Reig Monzón.
Finançador: Institut d'Investigacions Biomèdiques August Pi i Sunyer (Entidad de origen); Instituto de Salud Carlos III .

Codi: PI22/01427.

Durada: 01/01/2023 - 01/01/2025
IMMUNE4ALL, Exploring the Feasibility of predictive and pharmacodynamics biomarkers of immunotherapy in solid tumors

Investigador/a principal: María Reig Monzón.
Finançador: Institut d'Investigacions Biomèdiques August Pi i Sunyer (Entidad de origen); European Union - CIBERONC .

Codi: S2300092_3.

Durada: 01/01/2023 - 31/12/2025
Epithelioid Hemangioendothelioma International Network

Investigador/a principal: Jordi Rimola, María Reig Monzón.
Finançador: European Association for the Study of the Liver - EASL .

Codi: EHIN.

Durada: 01/06/2021 - 01/06/2026

Resum:
Project Title: Epithelioid Hemangioendothelioma International Network Project reference: N/A PI: Jordi Rimola Funding Agency: EASL Funding: 50000 eur Duration: 2021-2026
A European Cancer Image Platform Linked to Biological and Health Data for Next-Generation Artificial Intelligence and Precision Medicine in Oncology

Investigador/a principal: Jordi Rimola Gibert, Aleix Prat Aparicio.
Finançador: European Commission .

Codi: CE_H2020_SC1_20_1s13.

Durada: 01/10/2020 - 30/09/2024
"Improving immunotherapy in hepatocellular carcinoma via PD-1-TGFβ cotargeting"

Investigador/a principal: María Reig Monzón.
Finançador: CIBEReHD .

Codi: 20PI04.

Durada: 02/04/2020 - 01/04/2022

Resum:
Proyecto Competitivo Ciber.
Importancia del inflamasoma en la sensibilidad o resistencia a los inhibidores tirosina quinasa en pacientes con cáncer de hígado (PI18/00358) ( Importance of the inflammasome in the sensitivity or resistance to tyrosine kinase inhibitors in patients with

Investigador/a principal: María Reig Monzón.
Finançador: Instituto de Salud Carlos III .

Durada: 01/01/2019 - 31/12/2022
Rendimiento de la RM con ácido gadoxético para el diagnóstico y estadiaje del carcinoma hepatocelular

Investigador/a principal: Alejandro Forner Gonzalez.
Finançador: Instuto de Salud Carlos III ; Hospita Clinic de Barcelona (Sede o evento).

Codi: PI18/00542.

Durada: 01/01/2019 - 31/12/2021
AECC Clínico 2018: Prospective clinical evaluation of the genetic-immuno / inflammatory profile in the treatment of hepatocellular carcinoma with sorafenib to predict tolerance and survival"

Investigador/a principal: Alvaro Díaz González, María Reig Monzón.
Finançador: Asociación Española Contra el Cáncer (AECC). ; Asociación Española Contra el Cáncer (AECC) .

Codi: CLJUN18016DIAZ.

Durada: 01/08/2018 - 31/12/2019
A phase I open label, clinical trial evaluating the safety and anti-tumor activity of autologous T cells expressing enhanced TCRS specific for alpha-fetoprotein (AFP C332T) in HLA-A2 positive subjects with advanced hepatocellular carcinoma (HCC).

Investigador/a principal: Jordi Bruix Tudo.
Finançador: Adaptimmune .

Codi: ADP-0033-001.

Durada: 01/01/2018 - 31/12/2033

La recerca d'aquest grup es pot dur a terme gràcies als finançadors.

Projectes destacats

Rational to modulate the microbiome-induced endoplasmic reticulum stress as tool to avoid the immune evasion in Hepatocellular Carcinoma (RETO)

Plasticidad tumoral y la regulación de anhidrasa carbónica 9 en carcinoma hepatocelular. Base racional para modular la evasión inmunológica y mejorar la respuesta al tratamiento.

IMMUNE4ALL, Exploring the Feasibility of predictive and pharmacodynamics biomarkers of immunotherapy in solid tumors

Epithelioid Hemangioendothelioma International Network

A European Cancer Image Platform Linked to Biological and Health Data for Next-Generation Artificial Intelligence and Precision Medicine in Oncology

"Improving immunotherapy in hepatocellular carcinoma via PD-1-TGFβ cotargeting"

Importancia del inflamasoma en la sensibilidad o resistencia a los inhibidores tirosina quinasa en pacientes con cáncer de hígado (PI18/00358) ( Importance of the inflammasome in the sensitivity or resistance to tyrosine kinase inhibitors in patients with

Rendimiento de la RM con ácido gadoxético para el diagnóstico y estadiaje del carcinoma hepatocelular

AECC Clínico 2018: Prospective clinical evaluation of the genetic-immuno / inflammatory profile in the treatment of hepatocellular carcinoma with sorafenib to predict tolerance and survival"

A phase I open label, clinical trial evaluating the safety and anti-tumor activity of autologous T cells expressing enhanced TCRS specific for alpha-fetoprotein (AFP C332T) in HLA-A2 positive subjects with advanced hepatocellular carcinoma (HCC).

Finançadors principals